Business Description
Crescent Biopharma Inc
NAICS : 541714
SIC : 2834
ISIN : KYG2545C1042
Total Employee Number:
44Description
Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent's pipeline product CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. The company focuses on advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.
Financial Strength
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 122.59 | |||||
Equity-to-Asset | 0.92 | |||||
Debt-to-Equity | 0.01 | |||||
Debt-to-EBITDA | -0.01 | |||||
Piotroski F-Score | N/A/9 | |||||
Altman Z-Score | 15.63 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 31.38 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 39.9 | |||||
9-Day RSI | 44.42 | |||||
14-Day RSI | 45.87 | |||||
3-1 Month Momentum % | -13.21 | |||||
6-1 Month Momentum % | 45.26 | |||||
12-1 Month Momentum % | 13.36 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 13.78 | |||||
Quick Ratio | 13.78 | |||||
Cash Ratio | 13.33 | |||||
Days Sales Outstanding | 552.89 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History |
|---|
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Operating Margin % | -1372.85 | |||||
Net Margin % | -1363.94 | |||||
EBITDA Margin % | -1336.83 | |||||
FCF Margin % | -657.26 | |||||
OCF Margin % | -587.9 | |||||
ROE % | -100.86 | |||||
ROA % | -88.19 | |||||
ROIC % | -1349.79 | |||||
ROC (Joel Greenblatt) % | -7258.8 | |||||
ROCE % | -98.18 | |||||
Moat Score | 3 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 43.77 | |||||
PB Ratio | 2.62 | |||||
Price-to-Tangible-Book | 2.62 | |||||
EV-to-EBIT | -1.81 | |||||
EV-to-EBITDA | -1.81 | |||||
EV-to-Revenue | 24.16 | |||||
EV-to-FCF | -3.69 | |||||
| Price-to-Net-Current-Asset-Value | 2.67 | |||||
| Price-to-Net-Cash | 2.7 | |||||
Earnings Yield (Greenblatt) % | -55.25 | |||||
FCF Yield % | -16.52 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Crescent Biopharma Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 10.16 | ||
| EPS (TTM) (€) | -9.386 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | 72.85 | ||
| 14-Day RSI | 45.87 | ||
| 14-Day ATR (€) | 0.369692 | ||
| 20-Day SMA (€) | 14.68 | ||
| 12-1 Month Momentum % | 13.36 | ||
| 52-Week Range (€) | 6.7 - 22.8 | ||
| Shares Outstanding (Mil) | 27.57 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 9999 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Crescent Biopharma Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Crescent Biopharma Inc Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-06 | In 125 days | ||
| Second quarter earnings results for 2026 | 2026-07-31 | In 27 days | ||
| Goldman Sachs 47th Annual Global Healthcare Conference | 2026-06-08 08:40 | 15.10 (+0.00%) | ||
| Guidance call for 2026 | 2026-06-03 16:20 | 15.90 (+0.00%) | ||
| General meeting for 2025 | 2026-06-02 09:00 | 16.70 (+0.00%) | ||
| TD Cowen 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA | 2026-05-26 11:30 | 16.90 (+0.00%) | ||
| Guidance call for 2026 | 2026-05-20 14:30 | 15.10 (+0.00%) | ||
| Guidance call for 2026 | 2026-05-13 19:20 | 15.00 (+0.00%) | ||
| First quarter earnings results for 2026 | 2026-04-29 | 20.80 (+0.00%) | ||
| Annual report for 2025 | 2026-02-26 | 9.85 (+0.00%) |
Show
Entries
Crescent Biopharma Inc Frequently Asked Questions
What is Crescent Biopharma Inc(FRA:C68)'s stock price today?
The current price of FRA:C68 is €14.60. The 52 week high of FRA:C68 is €22.80 and 52 week low is €6.70.
When is next earnings date of Crescent Biopharma Inc(FRA:C68)?
The next earnings date of Crescent Biopharma Inc(FRA:C68) is 2026-07-31 Est..
Does Crescent Biopharma Inc(FRA:C68) pay dividends? If so, how much?
Crescent Biopharma Inc(FRA:C68) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Crescent Biopharma Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers